In the latest instalments of the Novartis sponsored DIAbetes Experts onLine (DIAL) webinar series, Professor Emeritus David Matthews, Professor Stefano del Prato, Professor Michael Stumvoll and Dr Païvi M. Paldánius discuss the key findings of the ground-breaking VERIFY trial and share their ideas about how these results might influence the way in which we treat early type 2 diabetes in the future.
Can type 2 diabetes disease progression be prevented? What are the risks of delaying escalation of type 2 diabetes treatment? Find out what Professor Stumvoll has to say.
The current recommendation for first-line treatment of hyperglycaemia in newly diagnosed type 2 diabetes patients is metformin monotherapy and lifestyle modifications, but is this enough? Professor Stumvoll examines the limitations of using monotherapy in the early treatment of type 2 diabetes and discusses the rationale behind the VERIFY study.
Is a combination of metformin and vildagliptin superior to metformin monotherapy in the early treatment of type 2 diabetes? Is combination therapy worthwhile in the first line of treatment and what are its long-term effects? Discover more about the questions at the heart of the VERIFY trial.
Find out more about the study design and key results of the VERIFY trial from chairman of the VERIFY steering committee, Professor David Matthews. Further insights are provided by Professor Stefano del Prato as he interprets the results of VERIFY from a clinical perspective, sharing his opinion on the impact this research is likely to have on future recommendations for first-line treatment of type 2 diabetes.
What does the future hold for early combination therapy? Find out what our experts think as they discuss several of the key queries raised around the results of the VERIFY trial.
The unexpected magnitude of the effect seen in the VERIFY trial has earned it a place in the consciousness of diabetes experts around the world. Does this study have the potential to fundamentally change the way we treat early type 2 diabetes? If so, how could combination therapy be used to achieve maximum patient benefit? Find out more from VERIFY contributors Professor David Matthews, Professor Stefano del Prato and Professor Michael Stumvoll in this informative Q&A session facilitated by Dr Païvi Paldánius.
In previous instalments of the Novartis sponsored DIAL webinar series, Dr Helmut Brath, Professor Dr Xavier Cos and Professor Chantal Mathieu address key issues around the important role of the physician in maintaining long-term medication adherence, the need for improved communication with patients and how individualising treatment can all help optimise diabetes treatment.
Is it time to do more? Dr Helmut Brath looks at the physician and patient barriers to treatment and discusses how to find a walkable way to help patients achieve their goals.
According to the EDGE study only 47% of patients adhere to their diabetes medication. But is this the fault of the physician or the patient? Dr Brath investigates how treatment should be evidence based and adapted to the individual with individualised goals and care to ensure the best possible outcomes.
How can individualised care be best delivered? What’s the best way to motivate patients in real life?
Professor Dr. Cos explores the barriers existing for both physicians and patients in type 2 diabetes management. He also provides examples of successful programmes that have been improving diabetes management through better communication and shared decision making.
See why it’s so important to put the patient at the centre of care. Professor Mathieu discusses the ADH / EASD 2015 guidelines and gives an overview of tailoring treatment according to patient characteristics.
For best management of diabetes it’s important to acknowledge the need for multifunctional treatment. Explore the American Diabetes Association / European Association for the Study of Diabetes (ADA / EASD) algorithm, and discover how differentiation of treatment choice should be based on individual patient characteristics, patient preference and involve shared decision making and a management plan that is regularly reviewed.